PET imaging study for solid tumors using CD147 targeting peptide probe
Treatments studied
Part of Cancer clinical trials.
This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of one of these cancers: melanoma, liver, colon, pancreatic, breast, stomach, or lung cancer.
- You are between 18 and 75 years old.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
- You have a tumor that can be measured on scans and biopsied within a month before and after the PET scan.
- You are willing to use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This trial studies whether a special PET scan probe that targets CLDN18.2 can help show solid tumors in the body. If you have a solid tumor that can be measured on scan, you may be invited to have imaging with the probe.
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
This trial tests a new imaging agent that targets TF-antigen, a molecule found on many solid tumors. The goal is to see if a PET scan can better detect and monitor cancers like lung, breast, or colon cancer.
This trial tests a new imaging agent that targets a protein called B7-H3 found on many solid tumors. It uses PET/CT to help doctors see and stage tumors more clearly.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.